A Phase 1b/2 study of derazantinib as monotherapy and combination therapy with paclitaxel, ramucirumab or atezolizumab in patients with HER2-negative gastric adenocarcinoma harboring FGFR genetic aberrations (FIDES-03)

  • Frentzas, Sophia (Primary Chief Investigator (PCI))

Project: Research

Project Details

Effective start/end date13/01/2112/01/26


  • phase 1 and 2 study
  • treatment efficacy
  • treatment safety
  • cancer treatment